The FDA has accepted a sNDA for Ameluz topical gel, used in combination with the RhodoLED red-light lamp series, for superficial basal cell carcinoma treatment.

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT ...

Highlight Therapeutics announces completion of enrollment for Phase 2b study of BO-112 in large, underserved basal cell ...

US FDA acknowledges no filing deficiencies in Biofrontera’s sNDA for Ameluz PDT in superficial basal cell carcinoma: Woburn, Massachusetts Saturday, February 14, 2026, 16:00 Hrs ...

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal ...

A study has examined whether there is a link between skin cancer found on the right side of the face and the side of the road ...

Verrica Pharmaceuticals Inc. ('Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling ...

The TV personality, 61, took to Instagram with a candid video as she opened up about her recent diagnosis.

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring ...

A routine cosmetic appointment turned into something far more serious for Kelli Finglass. She walked into her dermatologist’s office expecting nothing more than a skin check before cosmetic ...

Integrative analysis of immune ecotypes in skin cancers highlights metabolic reprogramming and macrophage polarization as key ...

Eylea was under pressure in 2025. Sales of Eylea plunged 42% in the United States to $2.7 billion, impacted by lower sales ...